Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06176625 · ClinicalTrials.gov registry record
Sight and Hearing Investigation Into Effects on Delirium
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 1,543
- Enrollment target
NCT06176625: Completed study, sponsored by Johns Hopkins University.
NCT06176625 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 1,543 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06176625 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 1,543 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn about sensory loss in hospital patients with delirium. The main questions it aims to answer are: * Are hearing and vision loss related to increased risk of having delirium? * Do hearing and vision loss contribute to more severe delirium? * Do sensory loss and/or delirium affect patient satisfaction with hospital care? Participants will be asked to: * answer delirium screening questions, * undergo hearing \& vision screenings, and * complete questionnaires about the hospital stay. The second part of this study is a clinical trial. Researchers will compare different hospital units to see if changing communication affects the number of patients with delirium. The main questions it aims to answer are: • Does sharing information about communication and/or providing hearing devices change the number of hospital patients with delirium? Participants in the study will be asked to complete delirium screenings and answer questions about their hearing and communication.
Primary Outcome
Diagnosis of delirium using 4AT Rapid Clinical Test for Delirium (4AT). This test has a score range of 0 to 12, with a score of 4 or more indicating a positive delirium result. A score between 1 and 3 is indicative of possible cognitive impairment. Delirium symptom severity can be informally inferred from the test score, but the study will not be using the 4AT Rapid Clinical Test for Delirium (4AT) to measure delirium severity.
Interventions
- BEHAVIORAL Communication Signage
- BEHAVIORAL Amplifier Use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,543 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2023-12-15 |
What the finished NCT06176625 record still lists
NCT06176625 is an observational study that tracks outcomes without assigning an intervention. Its 1,543 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Communication Signage is the first listed.
NCT06176625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06176625 about?
NCT06176625 is a clinical study titled "Sight and Hearing Investigation Into Effects on Delirium". The goal of this observational study is to learn about sensory loss in hospital patients with delirium. The main questions it aims to answer are: * Are hearing and vision loss related to increased risk of having delirium? * Do hearing and vision loss contribute to more severe delirium? * Do sensory...
What is the current status of trial NCT06176625?
This trial is currently completed. The enrollment target is 1,543 participants. The study started on 2023-01-11. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT06176625?
The interventions under investigation include: Communication Signage (BEHAVIORAL), Amplifier Use (BEHAVIORAL).
Who is sponsoring clinical trial NCT06176625?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI